Benedict Ameya Elizabeth, Hantman Graham, Paul Kavitha, Akbar Saeed
Acute Medicine, Ashford and St. Peter's NHS Trust, Surrey, GBR.
Respiratory Medicine, Ashford and St. Peter's NHS Trust, Surrey, GBR.
Cureus. 2024 Nov 14;16(11):e73673. doi: 10.7759/cureus.73673. eCollection 2024 Nov.
Protracted COVID-19 is increasingly recognised in immunocompromised patients, particularly those with haematological malignancies. Here, we present the case of a patient with protracted COVID-19 and an underlying B-cell malignancy. Standard COVID-19 treatment with remdesivir and steroids proved ineffective in this patient as she continued to have evolving ground-glass opacities on imaging. A multidisciplinary involvement altered treatment to include a combination of antivirals nirmatrelvir/ritonavir (Paxlovid) and remdesivir, a monoclonal antibody and immunoglobulins leading to a clinical cure. This report highlights the need for a more tailored approach in this patient sub-group than the rest of the population.
长期新冠在免疫功能低下的患者中越来越受到关注,尤其是那些患有血液系统恶性肿瘤的患者。在此,我们报告一例患有长期新冠且伴有潜在B细胞恶性肿瘤的患者病例。事实证明,对该患者采用瑞德西韦和类固醇进行标准的新冠治疗无效,因为她在影像学检查中持续出现新的磨玻璃影。多学科团队参与后调整了治疗方案,采用抗病毒药物奈玛特韦/利托那韦(帕罗韦德)和瑞德西韦联合治疗,同时使用单克隆抗体和免疫球蛋白,最终实现了临床治愈。本报告强调,对于这一患者亚组,需要采取比其他人群更具针对性(个性化)的治疗方法。